Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04946721 · ClinicalTrials.gov registry record
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
A clinical trial of Dry Eye Disease and oGVHD, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04946721 is a study of Dry Eye Disease and oGVHD that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 150 participants, below the 250-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04946721, a study of Dry Eye Disease and oGVHD, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate and study the immunologic changes to the ocular surface in cancer patients.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST The standard care exam and biological specimens' collection
Study Locations (1)
Maryland
- Geenebaum Cancer Center, University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04946721
The ClinicalTrials.gov registry entry for NCT04946721 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 250-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (40% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dry Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which The standard care exam and biological specimens' collection is the first listed.
NCT04946721 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04946721 about?
NCT04946721 is a clinical study titled "2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD". Evaluate and study the immunologic changes to the ocular surface in cancer patients.
What is the current status of trial NCT04946721?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2022-04-27. Estimated completion is 2027-12-31.
What conditions does trial NCT04946721 study?
This clinical trial studies the following conditions: Dry Eye Disease, oGVHD.
What interventions are being tested in trial NCT04946721?
The interventions under investigation include: The standard care exam and biological specimens' collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04946721?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04946721 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
RECRUITING · Phase 4
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.